osimertinib
astrazeneca
['bcsm', 'osimertinib']
 new horizons , at the annual meeting of the american society of clinical oncology ( ), it was demonstrated that the use of osimertinib, after chest surgery, significantly improved survival, compared to placebo, in an average follow-up of 5 years. #asco23 #bcsm 
MD @harvard ,MSc medical Oncology, #breastcancer & Researcher American Board Certified.Member of the European Society of Oncology. 𝒞ℴ𝒻𝒻ℯℯ ☕︎♥︎